We aimed to evaluate immunogenicity and adverse events (AEs) after a booster dose of
Meningococcal C conjugated (MCC) vaccine in HIV-infected children and adolescents, who …

Background: We aimed to evaluate the Meningococcal (Neisseria meningitidis) C
conjugated (MCC) vaccine seroconversion and adverse events (AEs) in HIV-infected and …

Objective: HIV-infected individuals (HIVI) are threatened by meningococcal infection and
presented lower response to vaccines. Data are scarce on long-term persistence of human …

Children and adolescents infected with HIV typically have a lower response to immunization
than do those in the general population. In most developed countries, meningococcal …

The significant increase in the incidence rates and ongoing outbreaks of serogroup C
meningococcal (MenC) disease, associated with the sequence type-103 complex, motivated …

Background: Human immunodeficiency virus (HIV)-infected children are at increased risk of
meningococcal infection and poor response to quadrivalent meningococcal conjugate …

Abstract Background The US Advisory Committee on Immunization Practices recommends a
booster dose of quadrivalent meningococcal conjugate vaccine (MCV4) after initial …

OBJECTIVE: To compare the immunogenicity of 1 vs 2 doses of meningococcal
polysaccharide conjugate vaccine (MCV4) in youth infected with human immunodeficiency …

Background Routine infant immunization with meningococcal C conjugate (MCC)
vaccination started in Brazil in November 2010, scheduled at three and five months plus a …

Objectives: To assess the epidemiology of meningococcal disease (MD) in Brazil and the
impact that recent evidence and lessons learned from the introduction of meningococcal C …